Literature DB >> 18972272

Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families.

Astrid Elisabeth Bruun Boilesen1, Marie Luise Bisgaard, Inge Bernstein.   

Abstract

OBJECTIVE: Women in hereditary non-polyposis colorectal cancer (HNPCC) families have an elevated risk of endometrial and ovarian cancer. The risk in Lynch syndrome families with known mutations in mismatch repair genes (MMR genes) seems to be higher than in familial colorectal cancer (CRC) families. Data in the Danish HNPCC register on the frequency and lifetime risk of gynecologic cancers were analyzed and the actual surveillance strategy discussed in relation to the results.
DESIGN: Register-based retrospective study.
METHOD: A total of 1,780 at-risk women were identified and epidemiological, clinical and MMR gene mutation data were retrieved.
RESULTS: In a total of 105 cases of endometrial cancer, there was no significant difference in MSH2, MSH6 and MLH1 mutation carrier frequency. Compared to the general population, mutation carriers had a 20 times increase in lifetime risk of endometrial cancer. Lifetime risk was elevated four times in familial CRC families. In these families, frequency was correlated to the pedigree phenotype, with significantly higher frequency demonstrated in Amsterdam II families compared to Amsterdam I families and families suspected of HNPCC. A total of 39 cases of ovarian cancer were identified with a lifetime risk of three to four times the general population. No significant correlation was found between the frequency of ovarian cancer and MMR gene mutation status in the families.
CONCLUSION: The benefit of surveillance concerning gynecological cancers seems to be less well founded in familial CRC families than in Lynch syndrome families. Modifying the surveillance strategy may be relevant in the future, but before changing existing guidelines concerning surveillance, further research is recommended.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18972272     DOI: 10.1080/00016340802443806

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  7 in total

1.  Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma.

Authors:  Andreas Obermair; Danny R Youlden; Joanne P Young; Noralane M Lindor; John A Baron; Polly Newcomb; Susan Parry; John L Hopper; Robert Haile; Mark A Jenkins
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

2.  Cancer risk in a cohort of subjects carrying a single mismatch repair gene mutation.

Authors:  D A Stupart; P A Goldberg; U Algar; R Ramesar
Journal:  Fam Cancer       Date:  2009-08-18       Impact factor: 2.375

3.  Decisions about prophylactic gynecologic surgery: a qualitative study of the experience of female Lynch syndrome mutation carriers.

Authors:  Holly Etchegary; Elizabeth Dicks; Kathy Watkins; Sabrina Alani; Lesa Dawson
Journal:  Hered Cancer Clin Pract       Date:  2015-03-19       Impact factor: 2.857

4.  Harmonisation of biobanking standards in endometrial cancer research.

Authors:  M Adishesh; A Fyson; S B DeCruze; J Kirwan; H M J Werner; D K Hapangama
Journal:  Br J Cancer       Date:  2017-06-29       Impact factor: 7.640

5.  Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer.

Authors:  Takashi Takeda; Kosuke Tsuji; Kouji Banno; Megumi Yanokura; Yusuke Kobayashi; Eiichiro Tominaga; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2018-01-30       Impact factor: 4.401

6.  Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China.

Authors:  Xiaopei Chao; Lei Li; Ming Wu; Shuiqing Ma; Xianjie Tan; Sen Zhong; Yalan Bi; Jinghe Lang
Journal:  Cancer Commun (Lond)       Date:  2019-07-15

Review 7.  Gender-Specific Aspects of Lynch Syndrome and Familial Adenomatous Polyposis.

Authors:  Ralph Schneider; Claudia Schneider; Christian Jakobeit; Alois Fürst; Gabriela Möslein
Journal:  Viszeralmedizin       Date:  2014-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.